| General Information | |
|---|---|
| ZINC ID | ZINC000036294665 |
| Molecular Weight (Da) | 519 |
| SMILES | Cc1c(C(=O)NCCc2ccc(Cl)cc2)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Cl)cc1 |
| Molecular Formula | C25Cl4N3O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 133.957 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 33 |
| LogP | 7.724 |
| Activity (Ki) in nM | 33.1131 |
| Polar Surface Area (PSA) | 46.92 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.073 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 23 |
| Fraction csp3 | 0.12 |
| Ilogp | 4.62 |
| Xlogp3 | 7.81 |
| Wlogp | 7.43 |
| Mlogp | 5.81 |
| Silicos-it log p | 7.51 |
| Consensus log p | 6.64 |
| Esol log s | -8.03 |
| Esol solubility (mg/ml) | 0.00000481 |
| Esol solubility (mol/l) | 9.26E-09 |
| Esol class | Poorly sol |
| Ali log s | -8.64 |
| Ali solubility (mg/ml) | 0.00000119 |
| Ali solubility (mol/l) | 2.29E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -11.42 |
| Silicos-it solubility (mg/ml) | 1.97E-09 |
| Silicos-it solubility (mol/l) | 3.79E-12 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.92 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.26 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.244 |
| Logd | 4.398 |
| Logp | 6.698 |
| F (20%) | 0.001 |
| F (30%) | 0.047 |
| Mdck | - |
| Ppb | 99.82% |
| Vdss | 1.396 |
| Fu | 1.63% |
| Cyp1a2-inh | 0.815 |
| Cyp1a2-sub | 0.428 |
| Cyp2c19-inh | 0.917 |
| Cyp2c19-sub | 0.067 |
| Cl | 2.331 |
| T12 | 0.034 |
| H-ht | 0.317 |
| Dili | 0.725 |
| Roa | 0.265 |
| Fdamdd | 0.962 |
| Skinsen | 0.03 |
| Ec | 0.003 |
| Ei | 0.019 |
| Respiratory | 0.055 |
| Bcf | 3.772 |
| Igc50 | 5.232 |
| Lc50 | 6.473 |
| Lc50dm | 6.608 |
| Nr-ar | 0.04 |
| Nr-ar-lbd | 0.007 |
| Nr-ahr | 0.805 |
| Nr-aromatase | 0.878 |
| Nr-er | 0.676 |
| Nr-er-lbd | 0.009 |
| Nr-ppar-gamma | 0.041 |
| Sr-are | 0.927 |
| Sr-atad5 | 0.64 |
| Sr-hse | 0.036 |
| Sr-mmp | 0.812 |
| Sr-p53 | 0.865 |
| Vol | 477.718 |
| Dense | 1.082 |
| Flex | 0.292 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.288 |
| Synth | 2.255 |
| Fsp3 | 0.12 |
| Mce-18 | 24 |
| Natural product-likeness | -1.187 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |